-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $8 Price Target

Benzinga·11/20/2026 11:22:01
Diffusion vocale
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $8 price target.